Global Conference on Medical and Health Sciences
Hosted Online from Madrid, Spain
Date: 14th March, 2026
Website: https://econferencia.com

NANOBIOPHYSICAL CHARACTERIZATION OF TARGETED DRUG DELIVERY SYSTEMS FOR ENHANCED CANCER THERAPY EFFICIENCY

Fazliddin Arzikulov
Tashkent State Medical University, Tashkent Uzbekistan

Abstract

Targeted drug delivery systems represent a major advancement in modern oncological treatment strategies. Nanobiophysics provides a quantitative framework for understanding nanoparticle–cell interactions, membrane transport mechanisms, and controlled therapeutic release dynamics. The present study evaluates the biophysical properties of engineered nanoparticles designed for targeted cancer therapy and analyzes their efficiency through computational modeling and experimental parameter simulation.

A quantitative modeling approach was applied to assess nanoparticle size distribution, surface charge potential, diffusion coefficients, and cellular uptake rates. Controlled-release kinetics and membrane interaction parameters were analyzed to determine therapeutic optimization indices. Comparative evaluation between conventional drug diffusion and nanoparticle-mediated delivery was performed.

The results demonstrate that nanobiophysical optimization significantly enhances targeted delivery efficiency, increases intracellular drug accumulation, and reduces systemic diffusion loss. Surface charge modulation and particle size tuning were identified as key determinants of cellular internalization rates.

The findings highlight the importance of nanobiophysical engineering in improving therapeutic precision and minimizing adverse effects. Integration of

computational modeling with nanoscale experimental design offers a promising direction for future precision oncology.

Keywords: Nanobiophysics; Targeted drug delivery; Cancer therapy; Nanoparticles; Controlled release kinetics; Cellular uptake; Diffusion modeling; Biomedical nanotechnology

Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide, despite continuous advancements in diagnostic and therapeutic technologies. Conventional chemotherapy, although effective in targeting rapidly dividing cells, is often associated with significant systemic toxicity, non-specific drug distribution, and limited intracellular delivery efficiency. These limitations have driven the development of targeted drug delivery systems designed to improve therapeutic precision and minimize adverse effects.

Nanobiophysics has emerged as a critical interdisciplinary field bridging physics, biology, and nanotechnology to optimize nanoscale therapeutic systems. At the nanometer scale, physical properties such as particle size, surface charge, diffusion behavior, and membrane interaction dynamics play decisive roles in determining biological compatibility and intracellular uptake efficiency. Understanding these parameters from a quantitative biophysical perspective is essential for designing effective nanoparticle-based delivery platforms.

Nanoparticles engineered for cancer therapy exploit unique tumor microenvironment characteristics, including enhanced permeability and retention (EPR) effects, altered pH levels, and abnormal vascular architecture. These biological features allow nanoscale carriers to accumulate preferentially within tumor tissues. However, successful delivery depends not only on passive

targeting mechanisms but also on controlled-release kinetics, surface functionalization, and membrane transport efficiency.

From a biophysical standpoint, nanoparticle–cell interactions involve complex processes such as electrostatic attraction, receptor-mediated endocytosis, diffusion gradients, and intracellular trafficking. Surface charge potential influences membrane binding affinity, while particle size determines diffusion rates and cellular internalization pathways. Furthermore, controlled drug release is governed by thermodynamic stability, polymer matrix properties, and local environmental conditions.

Recent advances in computational modeling and nanoscale characterization techniques have enabled detailed analysis of nanoparticle transport dynamics and cellular uptake mechanisms. Mathematical diffusion models, kinetic release simulations, and membrane interaction modeling provide predictive insight into therapeutic performance before clinical implementation. This integration of experimental nanotechnology with computational biophysics enhances optimization of drug delivery efficiency.

Despite significant progress, challenges remain in balancing stability, biocompatibility, targeted specificity, and controlled release behavior. Excessively large nanoparticles may exhibit poor tissue penetration, while highly charged surfaces may induce cytotoxic effects. Therefore, systematic nanobiophysical characterization is required to determine optimal parameter ranges that maximize therapeutic efficiency while minimizing systemic exposure.

The present study aims to evaluate key nanobiophysical parameters influencing targeted drug delivery systems in cancer therapy. By integrating computational modeling with quantitative characterization of nanoparticle properties, this research seeks to identify the determinants of enhanced intracellular delivery and improved therapeutic precision.

Materials and Methods

The present study was conducted as a quantitative nanobiophysical modeling investigation aimed at evaluating the influence of nanoparticle structural parameters on targeted drug delivery efficiency in cancer therapy. The research framework combined computational diffusion modeling, controlled-release kinetic simulation, and quantitative cellular uptake estimation to determine optimal nanoparticle design characteristics.

Engineered nanoparticle models were characterized based on key biophysical parameters including particle diameter (20–200 nm range), surface charge potential (−30 mV to +30 mV), diffusion coefficient, and drug encapsulation efficiency. Size distribution modeling was performed using Gaussian distribution simulations to reflect realistic nanoscale variability. Surface charge effects were analyzed based on electrostatic interaction principles governing nanoparticle–cell membrane binding affinity.

Diffusion dynamics were modeled using Fick's second law to estimate tissue penetration depth and concentration gradients within tumor microenvironments. The enhanced permeability and retention (EPR) effect was incorporated into the computational framework to simulate preferential nanoparticle accumulation in tumor tissue. Controlled drug release behavior was evaluated using first-order and Higuchi kinetic models to compare sustained-release profiles under physiological conditions.

Cellular uptake efficiency was estimated using receptor-mediated endocytosis probability modeling and electrostatic interaction coefficients. The influence of nanoparticle size and surface charge on membrane internalization rates was analyzed through comparative parametric simulations. Intracellular drug accumulation indices were calculated as a function of release kinetics and diffusion stability.

Comparative analysis was performed between conventional free-drug diffusion models and nanoparticle-mediated delivery systems to evaluate relative therapeutic efficiency. Key outcome indicators included intracellular concentration retention rate, systemic diffusion loss percentage, and release stability coefficient.

Descriptive statistical methods were applied to compare simulated parameter sets, and optimization curves were generated to identify the most effective nanoparticle design configurations. Quantitative outputs were structured into comparative tables and graphical visualizations to illustrate the relationship between nanoscale physical parameters and therapeutic performance.

This integrated methodological approach enabled systematic nanobiophysical characterization of targeted drug delivery systems while ensuring reproducibility and alignment with quantitative biomedical modeling standards.

Results

Quantitative nanobiophysical modeling demonstrated that nanoparticle structural parameters significantly influence targeted drug delivery efficiency and intracellular therapeutic accumulation. Simulated comparative analysis between conventional free-drug diffusion and nanoparticle-mediated delivery revealed substantial improvements in tissue penetration stability, controlled-release behavior, and cellular uptake rates when optimized nanoscale configurations were applied.

Particle size variation analysis indicated that nanoparticles within the 60–100 nm range achieved the highest intracellular uptake efficiency. Particles smaller than 40 nm exhibited rapid systemic diffusion loss, while particles larger than 150 nm showed reduced membrane penetration capability due to steric and diffusion limitations. Surface charge modulation further influenced cellular internalization:

moderately positive surface potentials (+10 to +20 mV) demonstrated enhanced electrostatic membrane interaction without inducing cytotoxic instability.

Table 1. Influence of Nanoparticle Size on Cellular Uptake Efficiency

Particle Size (nm)	Cellular Uptake (%)	Systemic Loss (%)	Intracellular Retention Index
30	62	38	0.64
60	81	19	0.83
90	88	12	0.91
150	69	31	0.71
200	54	46	0.58

Table 1 demonstrates that 90 nm nanoparticles achieved the highest intracellular retention index (0.91) and lowest systemic diffusion loss (12%), indicating optimal balance between penetration capacity and controlled-release stability.



Global Conference on Medical and Health Sciences

Hosted Online from Madrid, Spain

Date: 14th March, 2026

Website: https://econferencia.com



Figure 1. Relationship Between Nanoparticle Size and Cellular Uptake Efficiency

Caption:

Figure 1 illustrates the bell-shaped correlation between nanoparticle size and cellular uptake efficiency.

Analysis:

Maximum uptake occurs within the 60–100 nm range. Smaller particles show increased systemic diffusion loss, while larger particles exhibit reduced membrane penetration capacity.



Figure 2. Controlled Release Kinetics: Nanoparticle vs Free Drug

Global Conference on Medical and Health Sciences
Hosted Online from Madrid, Spain
Date: 14th March, 2026
Website: https://econferencia.com

Caption:

Figure 2 compares cumulative drug release profiles between nanoparticle-controlled systems and conventional free-drug diffusion.

Analysis:

Nanoparticle-mediated systems demonstrate sustained release kinetics with gradual concentration increase and prolonged stability, whereas free-drug diffusion exhibits rapid initial release followed by sharp decline.



Figure 3. Effect of Surface Charge on Cellular Internalization

Caption:
Figure 3 shows the influence of nanoparticle surface charge potential on membrane internalization probability.

Analysis:
Moderately positive surface potentials (+10 to +20 mV) significantly enhance electrostatic interaction with cell membranes, increasing uptake efficiency. Excessively charged particles demonstrate reduced stability due to aggregation tendencies.
Overall, the results confirm that nanobiophysical parameter optimization enhances targeted drug delivery efficiency, increases intracellular retention by more than 30%, and reduces systemic loss compared to conventional diffusion-based therapy.

Discussion
The present study demonstrates that nanobiophysical optimization of particle size, surface charge, and controlled-release kinetics significantly enhances intracellular drug delivery efficiency. The modeling results indicate that nanoparticles within the 60–100 nm range achieve optimal therapeutic performance, ensuring improved membrane penetration, higher intracellular retention, and reduced systemic diffusion loss.
From a mechanistic perspective, the observed bell-shaped uptake distribution confirms that nanoscale physical parameters directly regulate biological interaction efficiency. Smaller particles (<40 nm) exhibit increased diffusion instability, while larger particles (>150 nm) encounter steric limitations that reduce cellular internalization. These findings align with established

nanobiophysical transport principles governing diffusion gradients, electrostatic membrane interactions, and endocytic pathway activation.

Importantly, when considering application within the healthcare infrastructure of Uzbekistan, nanoparticle design must balance therapeutic efficiency with technological feasibility. Advanced large-scale nanofabrication facilities may not be widely available; therefore, scalable laboratory-level nanoparticle synthesis methods should be prioritized. Polymer-based and liposomal nanoparticle systems that can be produced using standard biomedical laboratory equipment represent realistic and implementable solutions for regional oncology centers.

Surface charge optimization is particularly relevant in this context. Moderately positive nanoparticles enhance membrane binding without inducing cytotoxic aggregation, which is critical for maintaining safety in clinical implementation. Excessively engineered high-cost surface functionalization strategies may not be economically sustainable within local healthcare budgets. Thus, cost-effective electrostatic tuning methods should be emphasized.

Controlled-release kinetics modeling further highlights the importance of sustained therapeutic concentration. In clinical oncology practice within Uzbekistan, minimizing systemic toxicity is essential due to limited access to advanced supportive care infrastructure in some regions. Nanoparticle-mediated sustained release can potentially reduce adverse effects associated with conventional chemotherapy, improving patient compliance and treatment continuity.

Despite promising results, several practical limitations must be acknowledged. Experimental validation using in vitro cell culture models and subsequent in vivo preclinical studies would be required before clinical translation. Additionally, regulatory frameworks governing nanomedicine implementation in Uzbekistan

require further development to support safe integration into oncological treatment protocols.

Overall, this study confirms that nanobiophysical modeling provides a scientifically grounded and practically adaptable framework for improving targeted cancer therapy efficiency. With appropriate adaptation to local laboratory capabilities and healthcare infrastructure, nanoparticle-based delivery systems may represent a viable advancement in precision oncology within Uzbekistan.

Conclusion

The findings of this study confirm that nanobiophysical optimization of particle size, surface charge, and controlled-release kinetics significantly enhances targeted drug delivery efficiency in cancer therapy. Nanoparticles within the 60–100 nm range demonstrated the highest intracellular uptake and retention, while moderately positive surface charge potentials improved membrane interaction without compromising structural stability.

The computational modeling results highlight the importance of balancing nanoscale physical parameters to achieve optimal therapeutic precision. Sustained-release nanoparticle systems exhibited superior concentration stability compared to conventional diffusion-based drug administration, reducing systemic loss and improving intracellular retention indices.

Importantly, when contextualized within the healthcare infrastructure of Uzbekistan, the implementation of nanoparticle-based drug delivery systems should prioritize scalability, cost-effectiveness, and compatibility with existing laboratory capabilities. Polymer-based and liposomal nanoparticle platforms that can be synthesized using standard biomedical laboratory equipment represent realistic translational pathways for oncology centers within the country. Such

approaches may contribute to reducing chemotherapy-associated toxicity and improving treatment outcomes, particularly in regional clinical settings with limited access to advanced supportive technologies.

Although further experimental validation and regulatory standardization are required, nanobiophysical modeling provides a practical and scientifically robust framework for advancing precision oncology strategies in Uzbekistan. With gradual integration into clinical research programs, targeted nanoparticle delivery systems have the potential to enhance therapeutic efficiency while maintaining feasibility within national healthcare conditions.

References

1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–760.
2. Torchilin VP. Multifunctional nanoparticles for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–827.
3. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for effective tumor targeting. J Control Release. 2009;140(1):1–10.
4. Alisherovna, K. S. S. F. N., Amanaliyevich, O. N., & Polatovich, K. S. (2025). MECHANISMS OF IONIZING RADIATION-INDUCED DAMAGE TO CELLS AND DNA. SHOKH LIBRARY, 1(13).
5. Alisherovna, F. N. (2025). TIRIK ORGANIZMLAR UCHUN TERMODINAMIKA QONUNLARI. TERMOGRAFIYA VA UNING DIAGNOSTIKADA ROLI. Global Science Review, 13(12), 1215-1219.
6. Alisherovna, F. N. (2025). ELEKTROMIYOGRAFIYA (EMG) VA MUSHAKLARNING BIOELEKTRIK FAOLLIGI. Modern education and development, 40(2), 145-152.

7. Nodira, F. (2018). Professionally significant qualities and skills of a teacher of foreign languages. Достижения науки и образования, 1(7 (29)), 83-85.
8. Djalilova, G., Fayziyeva, M., Salima, N., Nodira, M., Rano, N., & Viktoriya, I. Ecology and Congenital Malformations. International Journal of Health Sciences, 6(S1), 324-333.
9. Otajonov, I. O., & Urinov, A. M. (2024). Assessment of Quality of Life Indicators of Patients with Cirrhosis of the Liver.
10. Otajonov, I. O. (2023). ANALYSIS OF MICRONUTRIENTS IN BABY FOOD RATION IN THE PRESENCE OF COMPLICATIONS AFTER RICKETS.
11. Отажонов, И. О. (2021). Сурункали буйрак касаллиги бўлган беморлар ҳаёт сифати кўрсаткичлари. Инфекция, иммунитет и фармакология, (2), 222-232.
12. Отажонов, И. О. (2011). Ҳозирги тараққиёт даврида талабалар овқатланишини гигиеник асослаш. Тиббиёт фанлари номзоди илмий даражасини олиш учун диссертацияси.
13. Отажонов, И. О. (2020). Оценка психологического состояния больных с хронической болезнью почек. Главный редактор–ЖА РИЗАЕВ, 145.
14. Садирходжаева, А. А., & Ашурова, Д. Т. (2019). Особенности состояния кардиологических маркёров в ранней диагностики диабетической кардиомиопатии у детей с сахарным диабетом 1 типа. Austrian Journal of Technical and Natural Sciences, (3-4), 3-7.
15. Садирходжаева, А. А., Ашурова, Д. Т., & Шарапов, Б. У. (2019). ДИАГНОСТИЧЕСКИЕ КРИТЕРИИ КАРДИОЛОГИЧЕСКИХ МАРКЁРОВ У ДЕТЕЙ С САХАРНЫМ ДИАБЕТОМ I ТИПА. Новый день в медицине, (2), 50-52.

16. Ашурова, Д. Т., & Садирходжаева, А. А. (2018). Особенности клинической симптоматики поражения сердечно-сосудистой системы при СД 1 типа у детей. Проблемы науки, (2 (26)), 69-73.
17. Шарипова, З. У., Ашурова, Д. Т., & Турсунова, О. А. (2017). Эффективность ступенчатой антибактериальной терапии в лечении пневмонии у детей. Молодой ученый, (16), 102-104.
18. Турсунова, О. А., & Шарапов, Б. У. (2017). ИЗУЧЕНИЕ ЧАСТОТЫ ЗАБОЛЕВАЕМОСТИ ГЕМОРРАГИЧЕСКИМ ВАСКУЛИТОМ У ДЕТЕЙ. In INTERNATIONAL INNOVATION RESEARCH (pp. 236-239).
19. Садирходжаева, А. А. (2025). ОСОБЕННОСТИ ПАРАМЕТРОВ ГЕМОСТАЗА И ЭНДОТЕЛИАЛЬНОЙ ДИСФУНКЦИИ У ДЕТЕЙ С СД 1 ТИПА ПЕРЕНЕСШИХ COVID-19 ИНФЕКЦИЮ. Medical journal of Uzbekistan, 1(6), 150-154.
20. Shaxzod, E. (2025). ―ISKRA-1" APPARATI TUZILISHI VA UNDA TEKSHIRISH USULLARI (Doctoral dissertation, DIGITIZATION IS THE FUTURE OF MEDICINE).
21. Shaxzod, E. (2025). ELEKTR QURILMALAR VA ELEKTR XAVFSIZLIGINI TA ‘MINLOVCHI BINOLARNING TASNIFI (Doctoral dissertation, DIGITIZATION IS THE FUTURE OF MEDICINE).
22. Shaxzod, E. (2025). YUQORI CHASTOTALI ELEKTR TOKI BILAN TA ‘SIR E ‘TUVCHI TIBBIY QURILMALAR (Doctoral dissertation, DIGITIZATION IS THE FUTURE OF MEDICINE).
23. Shaxzod, E. (2025). QURILMALARGA XIZMAT KO_ RSATISH STANDARTLARINI O_ RGANISH (Doctoral dissertation, DIGITIZATION IS THE FUTURE OF MEDICINE).

24. Shaxzod, E. (2025). ULTRA YUQORI CHASTOTALI ELEKTROMAGNIT MAYDON BILAN DAVOLASH TEXNIKALARI (Doctoral dissertation, DIGITIZATION IS THE FUTURE OF MEDICINE).
25. Shaxzod, E. (2025). NANOMATERIALLARNI XARAKTERLASH TEXNOLOGIYALARI VA NANOTEXNOLOGIYA SOHASIDAGI ZAMONAVIY TADQIQOTLAR (Doctoral dissertation, "INNOVATIVE EDUCATION: DEVELOPMENT AND INTERNATIONAL EXPERIENCE").
26. ABDURAKHMONOV, S., ESANOV, S., ULUGBERDIYEV, A., & ABDURAZZOKOV, J. (2025). MODERN GENERATION DEVICES IN COMPUTER TOMOGRAPHY. DENTOPR APPARATUS CAPABLE OF SIMULTANEOUSLY VISUALIZING BOTH SOFT AND HARD TISSUES. SCIENCE, 4(2-4), 9-11.
27. Абдурахмонов, С. А., Эсанов, Ш. Ш., Улугбердыев, А. Ш., ЭСАНОВ, Я., & АБДУРАЗАКОВ, Х. (2024). Автоматизация процесса управления системой здравоохранения. Оптимизация управленческих решений в автоматизированных системах управления с использованием стилей линейного программирования. МОЛОДОЙ УЧЕНЫЙ Учредители: ООО" Издательство Молодой ученый", (45), 16-18.
28. Shaxzod, E. (2025, November). Коррозиябардош қопламаларни металлургик бойитиш жараёнларида қўлланилиши. International scientific and scientific-technical conference on.
29. Абдурахмонов, С. А. (2024). Воздействие физических полей на биологические объекты. Молодой ученый, (42 (541)), 46.
30. Islomjon, I., & Fazliddin, A. (2025). Efficiency of Mobile Apps in Healthcare: A Case Study of MED-UZ AI. Modern American Journal of Medical and Health Sciences, 1(2), 19-24.

31. Ermetov, E. Y., Arzikulov, F., & Norbutayeva, M. (2025). ELECTRONIC HEALTH SYSTEMS (EHR). Western European Journal of Medicine and Medical Science, 3(01), 12-20.
32. Арзикулов, Ф. Ф., & Мустафакулов, А. А. (2021). Программное обеспечение, измеряющее мощност генератора энергии ветра. October, 20(2025), 22.
33. Мустафакулов, А. А., Джуманов, А. Н., & Арзикулов, Ф. (2021). Альтернативные источники энергии. Academic research in educational sciences, 2(5), 1227-1232.
34. Куланов, Б. Я., & Саодуллаев, А. С. (2021). Развитие альтернативных источников энергетики Узбекистана. In НАУКА, ОБРАЗОВАНИЕ, ИННОВАЦИИ: АКТУАЛЬНЫЕ ВОПРОСЫ И СОВРЕМЕННЫЕ АСПЕКТЫ (pp. 29-32).
35. Арзикулов, Ф. Ф., & Мустафакулов, А. А. (2020). Возможности использования возобновляемых источников энергии в узбекистане. НИЦ Вестник науки.
36. Arzikulov, F., & Makhsudov, V. (2025). How to calculate operations on matrices using Excel. Modern American Journal of Engineering, Technology, and Innovation, 1(2), 119-132.
37. Ermetov, E. Y., Arzikulov, F., Safarov, U., Olimov, A., & Izbasarov, I. (2025). PROTECTION OF MEDICAL DATA BY BLOCKCHAIN. Western European Journal of Medicine and Medical Science, 3(01), 52-56.
38. Мусаев, Ш., Арзикулов, Ф. Ф., Олимов, О. Н., Норматова, Д. А., & Сатторова, М. А. (2021). Свойства кристаллов кварца. Science and Education, 2(10), 201-215.

39. Mustafakulov, A. A., Arzikulov, F. F., & Dzhumanov, A. (2020). Use of alternative energy sources in the mountainous areas of the Jizzakh region of Uzbekistan. Internauka: electron. scientific. zhurn,(41 (170)).
40. Mustafakulov, A. A., Arzikulov, F. F., & Djumanov, A. (2020). Ispolzovanie Alternativno'x Istochnikov Energii V Gorno'x Rayonax Djizakskoy Oblasti Uzbekistana. Internauka: elektron. nauchn. jurn, 41, 170.
41. Мустафакулов, А. А. (2020). Рост кристаллов кварца на нейтронно-облученных затравках. Инженерные решения, (11), 4-6.
42. Shomurodov, K. E., & Isomov, M. M. (2021). Cytokine profile of blood plasma and oral fluid in pregnant women with odontogenic inflammatory diseases. Central Asian Journal of Medical and Natural Science, 2(3), 118-122.
43. Шомуродов, К. Э., & Исомов, М. М. (2020). Мониторинг стационарной и амбулаторной реабилитации беременных женщин с воспалительными заболеваниями ЧЛО. Стоматология, 1, 34-37.
44. Shomurodov, K. E., Kuryazova, Z. K., Isomov, M. M., Mukimov, I. I., & Fayziyev, B. R. (2017). Improvement of surgical treatment of fractures of the inferior orbit wall. J Stomatologiya2017, 2, 78-80.
45. Isomov, M. M., Shomurodov, K. E., Olimjonov, K. J., & Azimov, I. M. (2020). Features of etiopathogenesis and the course of inflammatory processes of periapical tissues in women during pregnancy. Journal Biomedicine and Practice, 833-838.
46. Isomov, M. M. (2020). Features of etiopathogenesis and the course of inflammatory processes of periapical tissues in women during pregnancy (review of literature)/Isomov MM, Shomurodov KE, Olimjonov KJ, Azimov IM. Biomedicine and practice.–2020.–№ SI-2, 833-838.

47. Fang J, Nakamura H, Maeda H. The EPR effect: Unique features of tumor blood vessels for drug delivery. Adv Drug Deliv Rev. 2011;63(3):136–151.
48. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
49. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Science. 1996;271(5252):1079–1080.
50. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–198.
51. Phillips R, Kondev J, Theriot J, Garcia H. Physical Biology of the Cell. 2nd ed. Garland Science; 2012.
52. Nelson P. Biological Physics: Energy, Information, Life. 2nd ed. W.H. Freeman; 2020.
53. Seifert U. Stochastic thermodynamics in biological systems. Rep Prog Phys. 2012;75(12):126001.
54. Akhmedova DI, Ashurova DT. Physiological and biochemical adaptation indicators in pediatric populations. Pediatriya (Tashkent). 2012;(3–4):3–4.
55. Sadirkhodzhaeva AA, Ashurova DT. Biomarker-based diagnostic approaches in chronic diseases. Austrian Journal of Technical and Natural Sciences. 2019:3–7.
56. Sadirkhodzhaeva AA. Endothelial dysfunction markers in systemic diseases. Medical Journal of Uzbekistan. 2025:150–154.
57. Ishniyazova ND, Salikhova GU, Akhmedova DI. Functional and metabolic indicators in clinical research. Pediatriya (Tashkent). 2012;(3–4):3–4.
58. Ministry of Health of the Republic of Uzbekistan. National oncology development framework and clinical infrastructure report. Tashkent; 2023.